T-cell receptor recognizing idiotype- or KLH-derived peptides (TCR)

T-cell receptors (TCRs) recognizing idiotype- or KLH-derived peptides presented by MHC are specialized immune receptors that mediate targeted recognition of B-cell malignancies and vaccine components. The idiotype (Id) refers to the unique antigenic determinants within the variable regions of the immunoglobulin produced by a specific B-cell clone, making it a highly specific tumor-associated neoantigen in lymphomas and multiple myeloma (Brossart et al., 2000, Blood). Keyhole Limpet Hemocyanin (KLH) is a highly immunogenic carrier protein often conjugated to idiotype proteins to enhance immune responses by providing potent T-cell help through KLH-specific TCR recognition (Harris and Markl, 1999, Micron). These TCRs interact with peptide-MHC complexes on the surface of antigen-presenting cells or tumor cells, initiating signaling cascades that lead to T-cell proliferation, cytokine production, and direct lysis of malignant cells. Therapeutic applications include the development of personalized idiotype vaccines, such as BiovaxID, and the engineering of T-cells with specific TCRs for adoptive cell therapy (Levy et al., 2014, Journal of Clinical Oncology). Challenges in targeting these receptors include the requirement for patient-specific manufacturing and the potential for tumor escape through antigen loss or MHC downregulation.

Other names

Idiotype-specific T-cell receptorKLH-specific T-cell receptorId-specific TCRKLH-specific TCRTumor-specific T-cell receptor

Specific binding of the T-cell receptor to idiotype- or KLH-derived peptides presented on MHC molecules, triggering T-cell signaling, expansion, and effector functions such as cytokine release and tumor cell lysis.